Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (2)	2/24/1999 10:44:00 PM
From: LLCF	Read Replies (1) \| Respond to of 52153

<As I have accumulated what to me look like very cheap third tier biotech stocks, > How long can these things underperform the market... I mean they go nowhere during the rally... then sell off more % wise than the market during the sell off!!! Look at REGN,AXPH,CTII,CEPH,CHIR,NBIX,PARS,BTRN.... how many others? Hell, when this internet thing ends badly and the markets down 2000 points we all better have a couple hundred thou lying around cause you'll be able to buy 5% stakes in some of these if you want 'em! Get your 1/8 bid in for a quartermillion of each! Some dope will sell it. DAK

To: Mike McFarland who wrote (2)	2/24/1999 10:52:00 PM
From: Biomaven	Respond to of 52153

Mike, That's a pretty respectable list, but sort of a mixed bag in terms of type of stock. I'd characterize them like this: SEPR, MLNM, INCY: key biotech holdings of the "buy them and forget where you put the certificates" variety. None of them are cheap, but I think they are all good long-term value. CHIR - I think of them as a low-risk recovery play. Lots of cash and not enough discipline in the past, but the new CEO seems just what they need. Hard to know just what is going to drive the stock, but my hunch is something will turn up. I've owned a little since the mid-teens. ALXN - I like their C5 program a lot, but am scared a little by their "regaining their rights" to their xenotransplant stuff, despite their positive spin. I owned some 'til quite recently, and might re-enter at some point. AXPH - very cheap, but maybe destined to stay that way for now. REGN - also very cheap, but some real possibilities for a breakout (like Axokine). Mine departed in year-end tax-loss selling, but I keep a close eye on them (via Miljenko), and could re-enter at any moment. VRTX - also cheap, but I worry how their PI is going to do. Having an approved drug that doesn't do well is a downer for stock performance, no matter what the promise of the rest of their pipeline is. Never owned them personally, but they certainly bear watching. ENZN - in my "should follow but don't" basket. Peter